The Prostate
Journal
Overview
publication venue for
-
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.
2023
-
Prostate cancer genetic alterations in Hispanic men.
2023
-
Feasibility and preliminary clinical tolerability of low-field MRI-guided prostate biopsy..
83.
2023
-
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer..
83.
2022
-
Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution..
82.
2022
-
Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups..
82.
2022
-
Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients..
82.
2022
-
Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples..
82.
2022
-
Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer..
82.
2022
-
Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients..
82.
2021
-
Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients..
81.
2021
-
Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant..
81.
2021
-
Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients..
81.
2021
-
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns..
81.
2021
-
The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer..
81.
2021
-
Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy..
81.
2021
-
Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI..
81.
2021
-
The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients..
81.
2021
-
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer..
81.
2021
-
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer..
81.
2020
-
Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance..
80.
2020
-
PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study..
80.
2019
-
Response assessment using [68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer..
80.
2019
-
Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages..
78.
2018
-
Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion..
78.
2018
-
Influence of the neural microenvironment on prostate cancer..
78.
2017
-
Accuracy of Grading Gleason Score 7 Prostatic Adenocarcinoma on Needle Biopsy: Influence of Percent Pattern 4 and Other Histological Factors..
77.
2017
-
Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment..
77.
2017
-
Circulating Antioxidant Levels and Risk of Prostate Cancer by TMPRSS2:ERG..
77.
2017
-
North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer..
77.
2017
-
Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients..
77.
2016
-
Neuronal Trans-Differentiation in Prostate Cancer Cells..
76.
2016
-
The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker..
76.
2016
-
Predictors of biochemical recurrence in pT3b prostate cancer after radical prostatectomy without adjuvant radiotherapy..
76.
2015
-
Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC..
75.
2015
-
Evaluation of fatty acid synthase in prostate cancer recurrence: SUV of [(11) C]acetate PET as a prognostic marker..
75.
2015
-
Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor..
75.
2015
-
Delay from biopsy to radical prostatectomy influences the rate of adverse pathologic outcomes..
75.
2015
-
The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer..
75.
2015
-
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America..
75.
2015
-
Predictors of castration-resistant prostate cancer after dose-escalated external beam radiotherapy..
75.
2014
-
Utility of FDG-PET in clinical neuroendocrine prostate cancer..
74.
2014
-
Distribution of metastatic sites in patients with prostate cancer: A population-based analysis..
74.
2013
-
Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor..
73.
2013
-
Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells..
73.
2013
-
Negative regulation of NEP expression by hypoxia..
73.
2012
-
Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival..
73.
2012
-
External validation of the updated Briganti nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection..
73.
2012
-
Genetic variation in the toll-like receptor 4 and prostate cancer incidence and mortality..
72.
2011
-
A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study..
71.
2011
-
Gene expression pathways of high grade localized prostate cancer..
71.
2011
-
Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells..
71.
2010
-
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity..
70.
2010
-
Hepsin cooperates with MYC in the progression of adenocarcinoma in a prostate cancer mouse model..
70.
2010
-
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy..
69.
2009
-
Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer..
69.
2009
-
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence..
69.
2009
-
Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells..
69.
2009
-
Inactivation of the NF2 tumor suppressor protein merlin in DU145 prostate cancer cells..
68.
2008
-
The current state of preclinical prostate cancer animal models..
68.
2008
-
17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals..
67.
2007
-
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence..
67.
2007
-
Regulation of prostate 5alpha-reductase-2 gene expression and prostate weight by dietary fat and caloric intake in the rat..
66.
2006
-
Erythropoietin stimulates growth and STAT5 phosphorylation in human prostate epithelial and prostate cancer cells..
66.
2006
-
Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer..
65.
2005
-
Retinoic acid slows progression and promotes apoptosis of spontaneous prostate cancer..
61.
2004
-
Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia..
60.
2004
-
Differential expression of cell cycle regulatory molecules and evidence for a "cyclin switch" during progression of prostate cancer..
58.
2004
-
Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer..
58.
2004
-
Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate..
58.
2004
-
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice..
58.
2004
-
Familial aggregation of prostate cancer in African-Americans and white Americans..
56.
2003
-
Intermediate basal cells of the prostate: in vitro and in vivo characterization..
55.
2003
-
Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model..
55.
2003
-
Cellular senescence in the pathogenesis of benign prostatic hyperplasia..
55.
2003
-
MicroPET imaging of prostate cancer in LNCAP-SR39TK-GFP mouse xenografts..
55.
2003
-
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line..
55.
2003
-
The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer..
54.
2003
-
Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression..
54.
2003
-
Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses..
53.
2002
-
Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men..
50.
2002
-
Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study..
47.
2001
-
Characteristics of normal prostate vascular anatomy as displayed by power Doppler..
46.
2001
-
Leptin and prostate cancer..
46.
2001
-
Expression and localization of aminopeptidase A, aminopeptidase N, and dipeptidyl peptidase IV in benign and malignant human prostate tissue..
33.
1997
-
MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma..
33.
1997
-
Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy..
29.
1996
-
Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3..
24.
1994
-
TRPM-2 gene expression in normal rat ventral prostate following castration and exposure to diethylstilbestrol, flutamide, MK-906 (finasteride), and coumarin..
24.
1994
-
Comparison of the pathologic features and DNA ploidy value of prostate cancers detectable by sonography and by palpation..
23.
1993
-
Characterization of steroid receptors in human prostate using mibolerone..
8.
1986
-
Antigrowth effect of polyamine biosynthesis inhibitors on the Dunning R 3327-G prostatic tumor..
5.
1984
-
Physicochemical characterization of the androgen receptor from hyperplastic human prostate..
5.
1984
-
A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response..
4.
1983
-
The patient, disease status, and treatment options for prostate cancer: stages B1 and B2..
4.
1983
-
Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory..
3.
1982
-
Effect of estrogen on the mixed lymphocyte reaction in normal individuals and prostatic cancer patients..
3.
1982
-
Effects of estrogen administration on serum testosterone in Copenhagen rats..
3.
1982
-
Significance of prostatic biopsies after radiation therapy for carcinoma of the prostate..
3.
1982
-
Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI..
81.
2021
-
Workgroup 3: transgenic and reconstitution models of prostate cancer.
1998
-
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.
2023
-
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.
2020
-
Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
2018
-
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group.
2018
-
Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.
2016
-
Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.
2014
-
Future prospects in prostate cancer.
1999
-
Defeating prostate cancer: crucial directions for research--excerpt from the report of the Prostate Cancer Progress Review Group.
1999
Identity
ISO Abbreviation
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)